Autres langues Transgene

Actions

TNG

FR0005175080

Recherche biotechnologique et médicale

Marché Fermé - Euronext Paris 17:55:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,7000 ^EUR	-1,96%		-7,89%	-27,08%

25/09	Bourse : les Arnault à la Maison Blanche, HelloFresh avertit et Meta 2000
25/09	Transgene fait le point sur son activité

Autres langues

01/10	Transgene to Participate in Investor Access
01/10	Transgene to Participate in Investor Access
24/09	Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
24/09	2026 Half-Year Financial Report
24/09	Availability of Transgene’s Half-Year Financial Report as of June 30, 2026
24/09	Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2026
08/09	Transgene Expands ProBioGen Partnership With Additional License
08/09	Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
03/09	Transgene jumps 20% on positive cancer vaccine data in early trial
02/09	Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
02/09	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications
07/07	Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026
25/06	Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
25/06	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
22/06	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
26/05	Transgene : Investor presentation (20260526 Transgene Investor Presentation)
26/05	Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
22/05	Transgene’s Combined General Meeting of May 22, 2026
22/05	Transgene SA Announces Board Appointments
04/05	Transgene : Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
04/05	Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
29/04	Transgene : Finacial Report - (20260429 Transgene Q1 Results EN)
29/04	Transgene : Provides Business and Financial Update for Q1 2026